2017 CRS Annual Meeting: Call for Abstracts
Come join us at the 2017 CRS Annual Meeting, where science means business.
Don’t miss out on the opportunity to join the best and brightest in delivery science at the CRS Annual Meeting in Boston, July 16–19, 2017. Submit your abstracts now before submissions close January 20, 2017!
Attend the annual meeting to hear prominent scientists discuss the future of delivery science, learn about emerging technologies to solve our industry’s challenges, and participate in discussions relevant to the delivery science and technology area.
Abstracts will be accepted in the following session categories:
Advances in Manufacture, Characterization, Stability, and Regulation
This session will cover technology development through scale-up of commercially viable processes and methods to prepare and characterize products designed for controlled release of active materials. Some examples of process technologies include spray drying, hot-melt extrusion, co-precipitation, supercritical fluid technology, fluid bed coating, complex coacervation, 3D printing, inkjet printing, electrospinning, microfluidics, powder layering techniques, high-shear granulation techniques, membrane processes, and emulsion-based processes. The use of quality-by-design (QbD) and safety-by-design (SbD) concepts, analytical technologies for process end-point and real-time monitoring of preparation processes, imaging methods, and other approaches to ensure commercial viability are also critical to this area.
Invited Speakers:
• Diane Burgess, University of Connecticut, U.S.A
• Yue (Helen) Teng, U.S. Food & Drug Administration, U.S.A.
Biologically Active Excipients and Carriers
Most excipients are biologically inert, but there are those such as nonionic surfactants that can enhance absorption of drugs, or that like nonoxynol have a spermicidal effect. Examples of “active” excipients include the cyclodextrin sugammadex injected to bind and thus cease the action of vecuronium. Carrier systems themselves can have the ability to reduce toxin levels. This session hopes to explore and elucidate a wide range of such effects.
Invited Speakers:
• Daniel Kohane, Boston Children’s Hospital, U.S.A.
• Jean-Christophe Leroux, ETH Zurich, Switzerland
Cell Therapies
In silico science and technology have emerged in recent years, contributing to new drug design and development. They offer rational design of drugs. This session will cover all aspects of computational modeling in the field of drug delivery systems across this diverse range of products, including not only formulation and delivery efficiencies but also the microenvironment of tumors and the simulation of blood flow, digitalization of therapies, and so on.
Invited Speakers:
• Garry Duffy, Royal College of Surgeons in Ireland, Ireland
• David Mooney, Harvard University, U.S.A.
Delivery of Complex and Labile Molecules
The complexity of many new, often macromolecular, therapeutic agents clearly poses problems for their delivery by any route. This session is intended to explore potential avenues for the incorporation of such molecules in appropriate systems to preserve stability and maximize uptake and activity in vivo, as well as the challenges that each route of delivery poses. In cosmetic and food applications, labile molecules – often in complex multicomponent mixtures – have to be encapsulated for long-term stability in final formulations and triggered release in the correct ratio. This session also explores solutions for these application areas.
Invited Speakers:
• Victor Balcão, University of Sorocaba, Brazil
• Ana Jaklenec, MIT, U.S.A.
Delivery of Drug Combinations
In clinical settings, drugs are commonly administered in combination as a means to mitigate their associated toxicities. Recent research in the drug delivery field has sought to identify drug combinations with complementary mechanisms of action and mutually exclusive dose limiting toxicities. This session will focus on the rational identification of efficacious drug combinations as well as their formulation and development.
Invited Speakers:
• Glen Kwon, University of Wisconsin-Madison, U.S.A.
• Yi Yan Yang, Institute of Bioengineering and Nanotechnology, Singapore
Delivery Technologies in Nutraceuticals, Foods, and Oral Products
This session will include all aspects of oral delivery science and product development, including immediate, sustained, delayed, and pulsed release. It includes oral delivery of drugs (from small molecules to biologics), food, feed, beverages, nutrients, nutraceuticals, flavors, probiotics, prebiotics, and supplements. Topics of interest are broad and include, but are not limited to, all aspects of systems that enhance oral absorption, introduce prolonged effect and stability of additives, product acceptability (including taste masking, rheology, etc.), targeted and/or more uniform delivery in the gastrointestinal tract, in vitro and in vivo models, analytical chemistry, formulation technology for poorly soluble agents, biopharmaceutics, equipment design, and computational modeling.
Invited Speakers:
• Jingyuan Wen, University of Auckland, New Zealand
• Najie Zhang, PepsiCo, U.S.A.
Encapsulation and Controlled Release for Industrial Applications
This session focuses on advances in encapsulation and controlled release products in agrochemicals, agriculture, aquaculture, textiles, coating, adhesive, inks, and other industrial applications. Topics include, but are not limited to, more efficient biomass production for biofuels, genetic engineering (release of genetically engineered materials, enhancing organisms), anticorrosive and/or antifouling coatings (e.g., fish farms or offshore installations), self-healing coatings and materials (e.g., textiles), water storage systems, technologies for high-rise systems (fertilizing, light control), and more traditional areas involving controlled release of nutrients, vaccines, fertilizers, and pesticides.
Invited Speakers:
• To be named
Improving In Vitro Methodologies, Predicting Outcomes
A major obstacle in the development of effective and safe delivery systems is the lack of predictive in vitro systems to assess efficacy, tolerability, and immunogenicity. Such predictive assays would enable more efficient in vitro screening for down-selection of suitable candidates that are then tested in vivo. Within the last years, some progress on the development of more predictive assays has been seen. This session will focus on the recent advances of new methods that address the generation of relevant in vitro data that allow for better prediction of in vivo behavior of delivery systems.
Invited Speakers:
• Yvonne Perrie, University of Strathclyde, United Kingdom
• To be named
Medical Devices
Versatile types of medical devices have emerged in recent years, contributing to controlled drug administration, distribution, and metabolism. This session will cover all aspects of medical devices in the field of drug delivery systems across this diverse range of products, including microneedles, catheters, devices for regenerative medicines, gels, sutures, contact lenses, and so on.
Invited Speakers:
• Carlo Giovanni Traverso, MIT, U.S.A.
• To be named
Modeling and Simulation: Interplay of Animal and Human Pharmaceutical Development
There is tremendous similarity in the therapeutic needs impacting pharmaceutical product development in humans and dogs. Furthermore, because of their body size, ease of dosing, and ease of handling, the dog is often used as a preclinical species to support human formulation development. Conversely, given the wealth of information generated in support of human drug discovery and product development, human-derived data are often used as “preclinical” information for the dog. Given the significance of this knowledge exchange, it is important to identify those differences in gastrointestinal physiology and drug metabolism that can bias conclusions derived from these interspecies extrapolations. With that in mind, this session will provide state-of-the-art information on known differences in dog and human physiologies, explore the potential use of mechanistic models to facilitate the interspecies translation of oral bioavailability data, and provide some examples of how these in silico models can be used to support the development of human oral dosage forms.
Invited Speakers:
• Wen Lin, Norvatis, U.S.A.
• Marilyn Martinez, FDA Center for Veterinary Medicine, U.S.A.
New Directions for Polymers in Drug Delivery
Polymer science has been a driving force in drug delivery and delivery of active compounds in other application areas for more than 50 years. Polymeric materials can be rationally designed to control a number of key parameters including material-active interaction, degradability, and biocompatibility. This session will focus on novel approaches in the application of polymer-based materials science to improving drug delivery and delivery of active compounds in other industrial applications.
Invited Speakers:
• Ashutosh Chilkoti, Duke University, U.S.A.
• Nicholas Peppas, University of Texas at Austin, U.S.A.
Ocular Drug Delivery
Loss of eyesight has tremendous impact on quality of life. Treatment of numerous potentially blinding diseases can be improved with sustained, controlled drug delivery. However, the complex anatomy and physiology of the eye make designing effective drug delivery strategies challenging. This session will focus on recent advances in ocular drug delivery, including new materials for long-acting products that can be used to deliver both small and large molecules, surgical implants, remotely triggered drug release, and improved topical formulations.
Invited Speakers:
• Mikhail Ostrovsky, Russian Academy of Science, Russia
• Eliana Souto, University of Coimbra, Portugal
Overcoming Biological Barriers in Drug Delivery
Overcoming biological barriers is one of the major obstacles to the development of efficacious “next generation” delivery systems. The human body has exquisite mechanisms for maintaining health and homeostasis, which limit targeted, controlled, and sustained drug delivery. Similarly, the unique physiology of diseased states potentially presents additional barriers that must be overcome. This session will highlight advances in the development of drug delivery systems to overcome extracellular barriers (mononuclear phagocyte system, blood-brain barrier, blood-retinal barrier, mucosal barriers, tissue barriers, etc.) and cellular barriers (cell uptake, intracellular trafficking, endolysosomal pathway, etc.).
Invited Speakers:
• Wouter Hinrichs, University of Groningen, The Netherlands
• Christianna Rijcken, Cristal Therapeutics, The Netherlands
YSC Events & Activities at the Annual Meeting in Boston
For the 2017 annual meeting in Boston the Young Scientist Committee (YSC) has come up with an exciting program for the young scientists. Get your career kick started
with our new speed mentoring format, where you can talk to experienced people during breakfast in a relaxed atmosphere! Or you can build your network within the community during the Young Scientist Networking Event in a comfortable setting. Sharpen your leadership skills in our professional development workshop. Before the annual meeting, we will give you tips on oral and poster presentations on the CRS website, so check out the site. Become a part of the YSC and meet us during the conference when we go out on the town! We will make the conference an event that you will remember. See you in Boston!
